RT – 60mg

It represents a next generation incretin based analog developed to enhance receptor engagement, improve
molecular stability, and extend activity through fatty acid side chain acylation.
Within in vitro and in vivo experimental models, Triple Agonist (GLP-1 / GIP / Glucagon) has
been investigated for its coordinated receptor activity and downstream signaling effects,
including:
• Triple Receptor Co Activation – evaluated for concurrent GLP-1R, GIPR, and GCGR binding
and second messenger modulation
• Energy and Metabolic Regulatory Pathways – examined for combined receptor effects on
glucose handling and lipid metabolism in preclinical models
• Peptide Engineering and Acylation Modifications – studied for structural adaptations that
enhance half life, receptor selectivity, and signaling amplitude
This compound continues to be utilized in advanced metabolic and endocrinological research to
better understand poly agonist mechanisms and integrated receptor signaling across complex
metabolic networks.